This study therefore aimed to assess whether clinically used markers were associated with long-term survival and tamoxifen treatment benefit among patients with lymph node–negative, ER-positive/ERBB2-negative breast cancer by performing a secondary analysis of data from the Stockholm tamoxifen (STO-3) randomized clinical trial. The gene discussed is ERBB2; the disease is breast cancer.